Indication
Systemic Mastocytosis With an Associated Hematologic Neoplasm
3 clinical trials
4 products
Product
midostaurinClinical trial
An Open-label, Single Arm, Phase 2 Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic MastocytosisStatus: Active (not recruiting), Estimated PCD: 2026-01-31
Product
AvapritinibClinical trial
A Phase 1 Study of Avapritinib in Combination With Decitabine in Patients With Systemic Mastocytosis With an Associated Hematologic Neoplasm (SM-AHN)Status: Recruiting, Estimated PCD: 2027-03-01
Product
DecitabineProduct
Decitabine/Cedazuridine